Skip to main content
Clinical Trials/NCT06123221
NCT06123221RecruitingNot Applicable

COMPARISON OF IMPLANT INSTALLATION USING THE TRANSCRESTAL APPROACH WITH OSSEODENSIFICATION OR THE LATERAL WINDOW TECHNIQUE WITH SINUS LIFT: A RANDOMIZED CONTROLLED TRIAL.

Federal University of Rio Grande do Sul2 sites in 1 country38 target enrollmentStarted: October 1, 2022Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
38
Locations
2
Primary Endpoint
Pain level

Study Overview

Brief Summary

This study will compare patient-reported outcomes, as well as the type and incidence of complications, and bone marginal loss after 12 months in implants installed using the transcrestal approach (tSFE) with an osseodensification system (performed according to the protocol by Huwais et al. 2018), or installed simultaneously using the lateral window technique (lSFE) with sinus lift. A blind, randomized, controlled clinical trial will be carried out with individuals over 18 years old, and with single tooth loss in the posterior maxilla, where the residual bone height (RBH) is 3 to 5 mm. The tSFE will be performed with osseodensification burs (Densa Bur, Versah, USA) using a counterclockwise motion, associated to synthetic biomaterial (hydroxyapatite and beta-tricalcium phosphate). The lSFE technique will require the sinus to be filled with the same biomaterial as the group using the other technique, and the antrostomy to be covered with a polydioxanone-based membrane. The patient's post-operatory perceptions will be evaluated by self-administered questionnaires quantifying social and professional isolation, physical appearance, duration and changes in quality of life, eating and speech, diet variations, and sleep deficiency for 2 weeks after the procedure. Pain will be assessed with the visual analogue scale (VAS). Immediately after prosthetic rehabilitation, cone beam tomography will be performed. Controls at 6 and 12 months will be performed. In these images, the marginal bone level in relation to a fixed reference point on the implants (upper part of the platform) will be measured mesially and distally in each implant, using a specific program (ImageJ - version 1.49v / NIH software - Bethesda, MD, USA). Generalized estimating equations will be used to compare the two treatments overtime. The significance level used will be 0.05.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Investigator)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Maxillary sinuses that have residual bone height between at least 3 mm and 5 mm;
  • Width of the residual bone ridge that allows the insertion of an implant with a diameter of 4 mm;
  • Tomographic thickness of Schneider's membrane with a maximum of 5 mm in the region to be operated;
  • Residual ridge with ≥2 mm of medullary bone in the bucco-palatal direction, with a 1/1 ratio of medullary and cortical bone to achieve predictable plastic expansion;
  • Patients with adequate interarch space for placement of the prosthetic crown;
  • Good physical health status (ASA1 and ASA2, according to the Physical Status Classification System - American Society of Anesthesiologists);
  • At least 6 months since the last tooth loss in the region to be operated;

Exclusion Criteria

  • - Those with sinus pathology;
  • Heavy smokers (more than 10 cigarettes a day);
  • Those with a history of head and neck radiotherapy;
  • Those who have already undergone bone augmentation in any of the targeted surgical areas;
  • Immunodeficiency of any nature;
  • Emotional instability and psychiatric problems;
  • Pregnancy;
  • Current use of oral bisphosphonates or history of using injectable bisphosphonate;
  • Patients with active periodontitis defined by the presence of subgingival bleeding greater than 10%;
  • Documented allergy to drugs or dental materials involved in the experimental protocol.

Outcomes

Primary Outcomes

Pain level

Time Frame: day 14

visual analogue scale (VAS), ranging from "0 - no pain" to "100 - worst

Secondary Outcomes

  • Medication Diary (number of doses of Ibuprofen 600mg)(day 14)

Investigators

Sponsor
Federal University of Rio Grande do Sul
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Alex Nogueira Haas

Professor

Federal University of Rio Grande do Sul

Study Sites (2)

Loading locations...

Similar Trials